Latest News

This review summarizes state-of-the-art knowledge in early-generation and novel urine biomarkers targeting the telomerase pathway for the detection and follow-up of bladder cancer (BC). The limitations of the assays detecting telomerase reactivation are discussed and the potential of transcription-activating mutations in the promoter of the TERT gene detected in the urine as promising simple non-invasive […]

To determine the presence of a group of mutations, and establish the prognostic value for recurrence and progression. Prospective observational study. Intermediate-to-high-risk non-muscle invasive bladder cancer (NMIBC) was evaluated.

Disruption of the KEAP1-NRF2 pathway results in the transactivation of NRF2 target genes, consequently inducing cell proliferation and other phenotypic changes in cancer cells. Here, we demonstrated that GULP1 was a KEAP1-binding protein that maintained actin cytoskeleton architecture and helped KEAP1 to sequester NRF2 in the cytoplasm.

VHL mutations are the most common tumorigenic lesions in clear cell renal cell carcinoma (ccRCC) and result in continued activation of the HIF/VEGF pathway and uncontrolled cancer progression. Receptor tyrosine kinase (RTK) inhibitors such as sunitinib have been demonstrated to target tumorigenic signaling pathways, delay tumor progression, and improve patient prognosis in metastatic renal cell […]

Renal cell carcinoma (RCC) is one of the most common urologic malignant tumors. Current chemotherapy is not effective to RCC and results in some side-effects. Resveratrol (RSV) has been reported to exert anti-tumor effects in some cancer cells; however the mechanism is not fully understood.

Ashish Kamat: Welcome everybody to Uro Today’s Bladder Cancer Center of Excellence. I’m Ashish Kamat from Houston MD Anderson Cancer Center. It’s my pleasure today to welcome two giants in the field of pathology, Dr. Eva Comperat, and Hikmat Al-Ahmadie. Eva’s calling us right now from Austria, but she does most of her day job at […]

Ashish Kamat: Welcome, everybody to UroToday’s Bladder Cancer Center of Excellence. We are pleased today to be joined by Professor Marko Babjuk, who is an expert in the field of bladder cancer. He has sat on and led multiple clinical trials and is the chair of the EAU guidelines on non-muscle-invasive bladder cancer. He joins us […]

Cancer-specific survival for men with clinical stage I (CSI) seminoma approaches 100%, regardless of the management approach chosen after orchiectomy. Given the young age and high survival rate of these patients, there has been a shift toward minimizing treatment-related morbidity and cost.

The aim of this work is to review and synthesize the existing evidence and recommendations regarding to the therapeutic and surgical indications as well as monitoring of patients with Penile Cancer in COVID-19 era and to propose an action protocol to facilitate decision-making.

To evaluate the oncological feasibility of pure laparoscopic radical nephroureterectomy (p-LRNU) for upper tract urothelial carcinoma (UTUC) compared with conventional LRNU (c-LRNU) using a propensity-adjusted multi-institutional collaboration dataset.